With new Wegovy data in hand, Novo Nordisk will file for approval in MASH

Novo Nordisk’s weight loss drug Wegovy helped people with a fatty liver disease called MASH experience improvements in liver scarring and achieve symptom resolution, results the company sees as supporting regulatory approval.

After 72 weeks in a Phase 3 trial, 37% of patients on Wegovy experienced an improvement in liver scarring, or fibrosis, with no worsening of their disease. That compared with 23% of those on placebo, according to topline results Novo announced Friday.

Additionally, 63% of people on Wegovy achieved resolution of their symptoms with no worsening of fibrosis, compared with 34% of participants on placebo.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Kuros reports a 150% increase in direct MagnetOs sales in the first nine months of 2023 and announces changes within the Executive Management – Biotech Investments

Kuros Biosciences AG / Key word(s): Quarter Results 12-Oct-2023 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer

October 13, 2023

How health care organizations can set up chief medical officers for success

It should be obvious that medical school and clinical experience, in themselves, can’t fully prepare someone for the C-suite, any more than an MBA and

October 5, 2023

Dengue fever in Taiwan associated with elevated short- and long-term risk of depression

Analysis of the medical records of nearly 50,000 people who experienced dengue fever in Taiwan suggests that this disease is associated with elevated short- and

July 4, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.